http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-2.xsd
Current concepts in drug metabolism and toxicology
1 online resource (xi, 287 pages :) : illustrations (some color).
This new volume of Advances in Pharmacology explores the current concepts in drug metabolism and toxicology. Chapters cover the Keap1-Nrf2 cell defence pathway, Animal models of drug-induced idiosyncratic toxicity and the use of human embryonic and induced pluripotent stem cells for modelling metabolism and toxicity. With a variety of chapters and the best authors in teh field, the volume is an essential resource for Pharmacologists, Immunologists and Biochemists alike. Explores the current concepts in drug metabolism and toxicology Chapters cover such areas as the Keap1-Nrf2 cell defense pathway, animal models of drug-induced idiosyncratic toxicity and the use of human embryonic and induced pluripotent stem cells for modeling metabolism and toxicityAn essential resource for pharmacologists, immunologists and biochemists alike.
Front Cover; Current Concepts Indrug Metabolismand Toxicology; Copyright; Contents; Contributors; Membrane Transporters in Drug Development; Abstract; I. Introduction; II. Key Features of Transporters; III. Transporters and the Pharmaceutical Industry; IV. Studying and Contextualizing Transporter Interactions: Application and Interpretation of Data; VI. Conclusion; Acknowledgments; Abbreviations; References; The Keap1-Nrf2 Cell Defense Pathway -- A Promising Therapeutic Target?; Abstract; I. Introduction; II. The Keap1-Nrf2 Cell Defense Pathway
III. Activation of Nrf2 as a Potential Therapeutic StrategyIV. Inhibition of Nrf2 as a Potential Therapeutic Strategy; V. Conclusion; Acknowledgments; Abbreviations; References; Animal Models of Idiosyncratic Drug Reactions; Abstract; I. Introduction; II. Animal Models of Skin Rash; III. Animal Models of Liver Toxicity; IV. Animal Models of Hematological Toxicity; V. Animal Models of Generalized Hypersensitivity Reactions; VI. Animal Models of Generalized Autoimmunity; VII. Conclusion; Acknowledgments; Abbreviations; References
Genetic Polymorphisms Affecting Drug Metabolism: Recent Advances and Clinical AspectsAbstract; I. Introduction; II. Recent Advances in the Pharmacogenetics of Cytochromes P450; III. Recent Advances in the Pharmacogenetics of Non-P450 Metabolism; IV. Clinical Relevance of Polymorphic Metabolism -- Some Contemporary Examples; V. Conclusion; Abbreviations; References; Arylamine N-Acetyltransferases -- from Drug Metabolism and Pharmacogenetics to Identification of Novel Targets for Pharmacological Intervention; Abstract; I. Introduction; II. NAT Enzyme Mechanism; III. NAT Genes and Pharmacogenetics
IV. The Genomic Distribution and Function of NATsV. NAT Gene Expression and Regulation; VI. Development of NAT Inhibitors; VII. Conclusion; Acknowledgments; Abbreviations; References; Human Pluripotent Stem Cells for Modeling Toxicity; Abstract; I. Introduction; II. The Use of Human Stem Cells in Developmental Toxicity; III. The Use of Human Stem Cells in Cardiotoxicity; IV. The Use of Human Stem Cells in Hepatotoxicity; V. The Use of Human Stem Cells in Neurotoxicity; VI. Conclusion; Abbreviations; References; Disposition of Biologics; Abstract; I. Introduction; II. Routes of Administration
III. Mechanisms of Biologics Distribution and Clearance, The Importance of Active ProcessesIV. Distribution Studies with Biologics and Relevance to Toxicology Studies; V. Metabolism of Biologics; VI. Consideration of Immunogenicity -- Changes in Disposition and Impact on Toxicology; VII. Conclusion; References; Index; Recent Volumes in the Serial
Includes bibliographical references and index.
Drug-Related Side Effects and Adverse Reactions
Advances in pharmacology (San Diego, Calif.) ; 63